Centrient Pharmaceuticals Announces Achievement of Key Milestones in Clean Production of Antibiotics

Article content

Centrient Pharmaceuticals, Strict predicted no-effect concentration (PNEC) emission targets set by the AMR Industry Alliance to cleanly manufacture the entire product range of oral antibiotics. This standard covers both Centrient’s site and its supplier’s site. This achievement puts the company at the forefront of the industry by providing antibiotics manufactured with responsibility to minimize their contribution to antimicrobial resistance.

The PNEC emission target is the concentration of antibiotics in the water that is unlikely to be at risk of adverse environmental effects or the development of antimicrobial resistance (AMR). These scientific and risk-based targets are developed by the AMR Industry Alliance and target approximately 120 active pharmaceutical ingredients (APIs) used in the manufacture of antibiotics. Each antibiotic has a corresponding PNEC value and is published (updated regularly) in PNEC’s AMR Industry Alliance table recommended for risk assessment.

Article content

High concentrations of antibiotic residues in factory wastewater can create hotspots for resistant strains that can lead to AMR. Manufacturing only contributes to the emergence of AMR in the environment, but its impact cannot be overlooked. AMR poses a major threat to the global public health and medical industry. Many standard medical procedures, such as organ transplants, chemotherapy, and surgery such as caesarean section, are far more dangerous without effective antibiotics to prevent and treat the infection. Antibiotics are the cornerstone of our modern healthcare system, and by complying with PNEC standards, manufacturers can ensure that the supply of these critical drugs does not contribute to the risk of AMR.

Article content

PNEC values ​​are increasingly recognized as a measure of antibiotic emissions in water and are expanding beyond alliance companies and their supply chains. For example, the UK and German bids (health insurance company AOK) include specific references to PNEC emission targets. In addition, companies externally evaluated by organizations such as the Access to Medicine Foundation will be open to the public about their performance at PNEC.

As a strong advocate of sustainable manufacturing, Centrient Pharmaceuticals became a founding member of the AMR Industry Alliance in 2017 and worked with partners to raise awareness and provide solutions to AMR issues. Since then, the company’s unique path to full compliance has been to set up state-of-the-art wastewater treatment facilities at all sites around the world and develop tests to measure the antibiotic activity of wastewater streams. It includes chains that lead to a completely clean and PNEC compliant supply.

Article content

“”We are proud to announce the industry’s first PNEC compliance for the supply chain of oral antibiotic products.

At Centrient Pharmaceuticals, our commitment to sustainability is in DNA. In other words, the method of manufacturing a drug minimizes its environmental impact and does not contribute to AMR. We are proud of PureActives® Enzyme Low Carbon Technology, ISO 14001 certification for all sites, and the board of directors of the Pharmaceutical Supply Chain Initiative and the AMR Industry Alliance.

We will continue to work with customers, suppliers, industry and government decision makers throughout the value chain to make the supply and purchase of antibiotics sustainable to curb AMR.“, Rex Clements, CEO of Centrient Pharmaceuticals, says.

Article content

Read the white paper “Manufacturing Sustainable Antibiotics for the Future” here.

——————————————————————————————————————————

About Centrient Pharmaceuticals

Centrient Pharmaceuticals is a global leader in the manufacture and commercialization of sustainable antibiotics, next-generation statins, and antifungal agents. We manufacture and sell intermediates, active pharmaceutical ingredients, and finished dosage forms.

As a manufacturer of essential and life-saving medicines, we take pride in the heart of modern health care. With quality, reliability and sustainability at the heart of all our operations, we have more than 2,200 employees working continuously to meet our customers’ needs. We are committed to a sustainable future by actively participating in the fight against antimicrobial resistance.

Article content

Founded 150 years ago as “Nederlandsche Gisten Spiritus fabriek”, we were known as Gist Brocades, more recently DSM Sinochem Pharmaceuticals. Headquartered in Rijswijk (Netherlands), with production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient Pharmaceuticals is wholly owned by Bain Capital Private Equity, the world’s leading private investment company.

For more information, please visit www.centrient.com or contact Centrient Pharmaceuticals Corporate Communications, Alice Beijersbergen, Director Branding & Communications. Email: alice.beijersbergen@centrient.com.

About the AMR Industry Alliance

The AMR Industry Alliance was formed in 2017. With about 100 life sciences companies and industry associations, it accounts for almost one-third of sales and the majority of all new products. Members have promised to report on activities in the fields of research and science, access to antibiotics and their proper use, and responsible environmental manufacturing to address the rapid expansion of antimicrobial resistance. .. If the AMR is left unchecked, the annual death toll will increase from 700,000 to 10 million by 2050, and the economic impact could be comparable to the 2008 financial crisis. The AMR Industry Alliance collectively implements the specific commitments made by the signatories in the industry declaration on AMR and the roadmap for the progress of the fight against AMR, and measures the progress made in the fight against AMR. I guarantee that.

Article content

Description of future prospects

This press release may contain forward-looking statements regarding the future financial performance and position of Centrient Pharmaceuticals. Such statements are based on Centrient’s current expectations, estimates, forecasts, and information currently available to the company. Centrient warns the reader that such statements carry certain risks and uncertainties that are difficult to predict. Therefore, it is important to understand that many factors can significantly differ from these descriptions in actual performance and location. Centrient undertakes no obligation to update the statements contained in this press release except as required by law. The English version of the press release is dominant.